NovaBay Pharmaceuticals Inc. (AMEX:NBY) shares traded 1.40% higher at $0.51 on Wall Street last session.
In accordance with the data, 2 analysts cover NovaBay Pharmaceuticals Inc. (AMEX:NBY). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $9.50 and a low of $3.80, we find $6.65. Given the previous closing price of $0.50, this indicates a potential upside of 1230.0 percent. NBY stock price is now -24.22% away from the 50-day moving average and -62.15% away from the 200-day moving average. The market capitalization of the company currently stands at $2.04M.
It has been rated a hold by 0 analysts and a buy by 2. Brokers who have rated the stock have averaged $6.65 as their price target over the next twelve months.
With the price target of $1.10, Ladenburg Thalmann recently initiated with Buy rating for NovaBay Pharmaceuticals Inc. (AMEX: NBY).
In other news, Kunin Jeffrey, President, DERMAdoctor, LLC sold 1 shares of the company’s stock on Dec 06. The stock was sold for $2 at an average price of $1.81. Upon completion of the transaction, the President, DERMAdoctor, LLC now directly owns 0 shares in the company, valued at $0.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 06, Chief Product Officer Kunin Audrey sold 1 shares of the business’s stock. A total of $2 was realized by selling the stock at an average price of $1.81. Insiders disposed of 11,922 shares of company stock worth roughly $6080.22 over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NBY stock. A new stake in NovaBay Pharmaceuticals Inc. shares was purchased by TOWER RESEARCH CAPITAL LLC (TRC) during the first quarter worth $6,000.
NovaBay Pharmaceuticals Inc. (AMEX: NBY) opened at $0.5400 on Thursday. During the past 12 months, NovaBay Pharmaceuticals Inc. has had a low of $0.48 and a high of $6.58. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 2.20, and a quick ratio of 1.40. The fifty day moving average price for NBY is $0.6652 and a two-hundred day moving average price translates $1.3319 for the stock.
The latest earnings results from NovaBay Pharmaceuticals Inc. (AMEX: NBY) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$1.27, missing analysts’ expectations of -$0.55 by -0.72. This compares to -$1.43 EPS in the same period last year. The company reported revenue of $4.61 million for the quarter, compared to $3.66 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 25.89 percent. For the current quarter, analysts expect NBY to generate $3.55M in revenue.
Moreover, the firm recently paid out its quarterly dividend on 07/03/2006. Investors who held shares on 06/16/2006 were paid a $0.25 dividend.
NovaBay Pharmaceuticals Inc.(NBY) Company Profile
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
